Biogen's new spine disease drug outperformed expectations during its commercial debut.
Jim Cramer looks at how the French elections are smacking the U.S stock markets. Plus, he has the week-ahead game plan for oil and stocks.
These four stocks are showing short-term gain catalysts and longer-term growth potential.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.